 |
|
|
| |
VX-135, A Once-daily Nucleotide HCV Polymerase Inhibitor, Was Well Tolerated And Demonstrated Potent
Antiviral Activity When Given With Ribavirin In Treatment-naïve Patients With Genotype 1 HCV
|
| |
| |
Reported by Jules Levin
AASLD Washington DC 2013, Nov 2-5
Serghei Popa1, Alina Berliba1, Nelea Ghicavii2, Alain A. Patat5, Robert S. Kauffman3, Julie Krop3, Varun Garg3, Myron Tong4, Sushmita M. Chanda6, Qingling Zhang6,
Christopher Westland6, Matthew W. McClure6, Leo Beigelman6, Lawrence M. Blatt6, John Fry6
1. Republican Clinical Hospital, Chisinau, Moldova, 2. Arensia Exploratory Medicine, Chisinau, Moldova, 3. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA.
4. Liver Center, Huntington Medical Research Institutes, Pasadena, CA, USA, 5. BioTrial, Rennes, France,6. Alios BioPharma Inc, South San Francisco, CA, USA
References
1. Wang, H-Y.; McGuigan, C. Future Medicinal Chemistry 2012, 4(5), 625-650.
2. Marcellin, P et al: ALS-2200, A novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-naïve patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C. EASL Poster 866, April 2013.
|
| |
|
|
|
|
|
